SCHEMBL573396

SCHEMBL573396

CC(N)(CC(N)=O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 1/20 0.46
NOS2 P35228 5/20 0.43
ARG1 P05089 1/20 0.42
ARG2 P78540 1/20 0.42
BLM P54132 2/20 0.41
NOS1 P29475 3/20 0.40
TSHR P16473 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
HIF1A Q16665 1/20 0.40
NOS3 P29474 1/20 0.40
ALDH1A1 P00352 4/20 0.37
ADRA1A P35348 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 2/20 0.37
CYP1A2 P05177 2/20 0.37
KMT2A Q03164 2/20 0.37
USP2 O75604 1/20 0.37
EGFR P00533 1/20 0.37
FYN P06241 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161722 1.00 GGT1 (0.46) GGT1NOS2ARG1ARG2BLM
SCHEMBL161723 1.00 GGT1 (0.46) GGT1NOS2ARG1ARG2BLM
Asparagine SCHEMBL7046551 0.82 GRIK1 (0.42) GGT1BLMKMT2AALOX15PMP22
SCHEMBL28453562 0.81 FDPS (0.33) GGT1NOS2ARG1ARG2BLM
SCHEMBL9823655 0.81 FDPS (0.33) GGT1NOS2ARG1ARG2BLM
SCHEMBL28610049 0.81 FDPS (0.33) GGT1NOS2ARG1ARG2BLM
SCHEMBL1875520 0.81 TSHR (0.55) GGT1NOS2ARG1ARG2BLM
SCHEMBL162455 0.81 TSHR (0.55) GGT1NOS2ARG1ARG2BLM
SCHEMBL1660876 0.81 TSHR (0.55) GGT1NOS2ARG1ARG2BLM
SCHEMBL1986433 0.79 GGT1 (0.46) GGT1NOS2ARG1ARG2BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160318987-A1 PROTEASE RESISTANT PEPTIDES MEDIMMUNE LIMITED (GB) 2016-11-03 US claimed
WO-2026107423-A1 ORAL PEPTIDES AND USES THEREOF FOR WEIGHT LOSS, WEIGHT MAINTENANCE, AND MANAGEMENT OF METABOLIC CONDITIONS METSERA, INC. (US) 2026-05-21 WO disclosed
EP-4626479-A1 COMPOSITIONS AND METHODS FOR PROTEIN INTERNALIZATION Lytica Therapeutics, Inc. (US) 2025-10-08 EP disclosed
US-20240201179-A1 FLUOROGENIC SENSORS FOR DETECTING ANTIGENS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-06-20 US disclosed
US-20240182532-A1 MICROPEPTIDES AND USES THEREOF FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) 2024-06-06 US disclosed
WO-2024119049-A1 COMPOSITIONS AND METHODS FOR PROTEIN INTERNALIZATION LYTICA THERAPEUTICS, INC. (US) 2024-06-06 WO disclosed
US-20240174723-A1 STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF LYTICA THERAPEUTICS, INC. (US) 2024-05-30 US disclosed
US-20240124525-A1 PROLINE-LOCKED STAPLED PEPTIDES AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2024-04-18 US disclosed
EP-4351656-A1 PEPTIDES COMPRISING N-FORMYL-HALOGENATED METHIONINE RESIDUES AND ENGINEERED ANTIBODY-PEPTIDE CONJUGATES THEREOF Eli Lilly and Company (US) 2024-04-17 EP disclosed
CN-117750981-A Peptides comprising N-formyl-halomethionine residues and engineered antibody-peptide conjugates thereof 伊莱利利公司 2024-03-22 CN disclosed
WO-2011002955-A2 METHODS FOR MAKING EMBRYONIC CELLS, EMBRYOS, AND ANIMALS SENSITIZED TO STRESS BRANDEIS UNIVERSITY (US) 2011-01-06 WO disclosed
US-20100184645-A1 STITCHED POLYPEPTIDES PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2010-07-22 US disclosed
WO-2010025510-A1 LIBRARIES OF PEPTIDE CONJUGATES AND METHODS FOR MAKING THEM XENOME LTD (AU) 2010-03-11 WO disclosed
EP-1261360-B1 CASEIN DERIVED PEPTIDES AND USES THEREOF IN THERAPY PEPTERA PHARMACEUTICALS LTD (IL) 2009-12-16 EP disclosed
EP-1033999-A4 COMPOSITIONS OF LEUKAEMIA INHIBITORY FACTOR AMRAD OPERATIONS PTY LTD (AU) 2004-11-03 EP disclosed
CN-1351663-A Viral variants NORTH WESTER HEALTH CARE NETWO (AU) 2002-05-29 CN disclosed
EP-1033999-A1 COMPOSITIONS OF LEUKAEMIA INHIBITORY FACTOR Amrad Operations Pty.,Ltd. (AU) 2000-09-13 EP disclosed
WO-1999027950-A1 COMPOSITIONS OF LEUKAEMIA INHIBITORY FACTOR AMRAD OPERATIONS PTY. LTD. (AU) 1999-06-10 WO disclosed
WO-1999014243-A1 IMMUNOINTERACTIVE MOLECULES AND USES THEREFOR CONE ROBERT EDWARD (US) 1999-03-25 WO disclosed
WO-1998048011-A1 NOVEL CHIMERIC MOLECULES THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 1998-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240201179-A1 FLUOROGENIC SENSORS FOR DETECTING ANTIGENS CD2BP2, CD69, LY96 GGT1 983/4885NOS2 3284/4885ARG1 4504/4885
US-20100184645-A1 STITCHED POLYPEPTIDES VIP, IAPP, NGLY1 GGT1 1030/4885NOS2 3723/4885ARG1 3301/4885
US-20240124525-A1 PROLINE-LOCKED STAPLED PEPTIDES AND USES THEREOF PRAP1, PRR12, NPPA GGT1 1272/4885NOS2 2179/4885ARG1 1137/4885
US-20240174723-A1 STAPLED ANTIMICROBIAL PEPTIDES (STAMPS) AND USES THEREOF NGLY1, MDN1, SPPL2B GGT1 2173/4885NOS2 2013/4885ARG1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.